About this Journal Submit a Manuscript Table of Contents
Journal of Biomedicine and Biotechnology
Volume 2011 (2011), Article ID 406473, 10 pages
http://dx.doi.org/10.1155/2011/406473
Review Article

Roles of the WHHL Rabbit in Translational Research on Hypercholesterolemia and Cardiovascular Diseases

1 Institute for Experimental Animals, Kobe University Graduate School of Medicine, 7-5-1, Kusunoki-cho, Chuo-ku, Kobe 650-0017, Japan
2Section of Animal Models for Cardiovascular Disease, Division of Cardiovascular Medicine, Kobe University Graduate School of Medicine, 7-5-1, Kusunoki-cho, Chuo-ku, Kobe 650-0017, Japan

Received 10 September 2010; Revised 17 January 2011; Accepted 15 February 2011

Academic Editor: Andrea Vecchione

Copyright © 2011 Tsutomu Kobayashi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. World Health Organization, The World Health Report 2002—Reducing Risks, Promoting Healthy Life: Statistical Annex, World Health Organization, Geneva, Switzerland, 2002.
  2. T. Teramoto, J. Sasaki, H. Ueshima et al., “Executive summary of Japan Atherosclerosis Society (JAS) guideline for diagnosis and prevention of atherosclerotic cardiovascular diseases for Japanese,” Journal of Atherosclerosis and Thrombosis, vol. 14, no. 2, pp. 45–50, 2007. View at Scopus
  3. S. Yusuf and S. Anand, “Cost of prevention: the case of lipid lowering,” Circulation, vol. 93, no. 10, pp. 1774–1776, 1996. View at Scopus
  4. A. Endo, M. Kuroda, and Y. Tsujita, “ML 236A, ML 236B, and ML 236C, new inhibitors of cholesterogenesis produced by Penicillium citrinum,” Journal of Antibiotics, vol. 29, no. 12, pp. 1346–1348, 1976. View at Scopus
  5. Y. Tsujita, M. Kuroda, and Y. Shimada, “CS-514, a competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase: tissue-selective inhibition of sterol synthesis and hypolipidemic effect on various animal species,” Biochimica et Biophysica Acta, vol. 877, no. 1, pp. 50–60, 1986. View at Scopus
  6. Y. Watanabe, “Studies on characteristic of spontaneously hyperlipidemic rabbit and development of the strain with such property,” Bulletin of Azabu Veterinary College, vol. 2, no. 1, pp. 99–124, 1977 (Japanese).
  7. T. V. Liew and K. K. Ray, “Intensive statin therapy in acute coronary syndromes,” Current Atherosclerosis Reports, vol. 10, no. 2, pp. 158–163, 2008. View at Publisher · View at Google Scholar · View at Scopus
  8. M. Shiomi and T. Ito, “The Watanabe heritable hyperlipidemic (WHHL) rabbit, its characteristics and history of development: a tribute to the late Dr. Yoshio Watanabe,” Atherosclerosis, vol. 207, no. 1, pp. 1–7, 2009. View at Publisher · View at Google Scholar · View at Scopus
  9. Y. Watanabe, T. Ito, and T. Kondo, “Breeding of a rabbit strain of hyperlipidemia and characteristic of these strain,” Experimental Animals, vol. 26, no. 1, pp. 35–42, 1977 (Japanese).
  10. Y. Watanabe, “Serial inbreeding of rabbits with hereditary hyperlipidemia (WHHL-rabbit). Incidence and development of atherosclerosis and xanthoma,” Atherosclerosis, vol. 36, no. 2, pp. 261–268, 1980. View at Scopus
  11. K. Tanzawa, Y. Shimada, and M. Kuroda, “WHHL-rabbit: a low density lipoprotein receptor-deficient animal model for familial hypercholesterolemia,” FEBS Letters, vol. 118, no. 1, pp. 81–84, 1980. View at Publisher · View at Google Scholar · View at Scopus
  12. R. J. Havel, T. Kita, and L. Kotite, “Concentration and composition of lipoproteins in blood plasma of the WHHL rabbit. An animal model of human familial hypercholesterolemia,” Arteriosclerosis, vol. 2, no. 6, pp. 467–474, 1982. View at Scopus
  13. T. Kita, M. Brown, D. W. Bilheimer, and J. L. Goldstein, “Delayed clearance of very low density and intermediate density lipoprotein with enhanced conversion to low density lipoprotein in WHHL rabbits,” Proceedings of the National Academy of Sciences of the United States of America, vol. 79, no. 18, pp. 5693–5697, 1982. View at Scopus
  14. T. Kita, J. L. Goldstein, and M. S. Brown, “Hepatic uptake chylomicron remnants in WHHL rabbits: a mechanism genetically distinct from the low density lipoprotein receptor,” Proceedings of the National Academy of Sciences of the United States of America, vol. 79, no. 11, pp. 3623–3627, 1982.
  15. J. M. Dietschy, T. Kita, and K. E. Suckling, “Cholesterol synthesis in vivo and in vitro in the WHHL rabbit, an animal with defective low density lipoprotein receptors,” Journal of Lipid Research, vol. 24, no. 4, pp. 469–480, 1983. View at Scopus
  16. Y. Watanabe, T. Ito, and M. Shiomi, “The effect of selective breeding on the development of coronary atherosclerosis in WHHL rabbits. An animal model for familial hypercholesterolemia,” Atherosclerosis, vol. 56, no. 1, pp. 71–79, 1985. View at Scopus
  17. M. Shiomi, T. Ito, M. Shiraishi, and Y. Watanabe, “Inheritability of atherosclerosis and the role of lipoproteins as risk factors in the development of atherosclerosis in WHHL rabbits: risk factors related to coronary atherosclerosis are different from those related to aortic atherosclerosis,” Atherosclerosis, vol. 96, no. 1, pp. 43–52, 1992. View at Scopus
  18. M. Shiomi, T. Ito, S. Yamada, S. Kawashima, and J. Fan, “Development of an animal model for spontaneous myocardial infarction (WHHLMI rabbit),” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 23, no. 7, pp. 1239–1244, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  19. M. Shiomi and J. Fan, “Unstable coronary plaques and cardiac events in myocardial infarction-prone Watanabe heritable hyperlipidemic rabbits: questions and quandaries,” Current Opinion in Lipidology, vol. 19, no. 6, pp. 631–636, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  20. M. Shiomi, T. Ito, T. Tsukada, T. Yata, and M. Ueda, “Cell compositions of coronary and aortic atherosclerotic lesions in WHHL rabbits differ: an immunohistochemical study,” Arteriosclerosis and Thrombosis, vol. 14, no. 6, pp. 931–937, 1994. View at Scopus
  21. M. Shiomi, T. Ito, T. Fujioka, and Y. Tsujita, “Age-associated decrease in plasma cholesterol and changes in cholesterol metabolism in homozygous Watanabe heritable hyperlipidemic rabbits,” Metabolism, vol. 49, no. 4, pp. 552–556, 2000. View at Scopus
  22. T. Ito, S. Yamada, and M. Shiomi, “Progression of coronary atherosclerosis relates to the onset myocardial infarction in an animal model of spontaneous myocardial infarction (WHHLMI rabbits),” Experimental Animals, vol. 53, no. 4, pp. 339–346, 2004. View at Publisher · View at Google Scholar · View at Scopus
  23. H. O. Mowri, S. Ohkuma, and T. Takano, “Monoclonal DLR1a/104G antibody recognizing peroxidized lipoproteins in atherosclerotic lesions,” Biochimica et Biophysica Acta, vol. 963, no. 2, pp. 208–214, 1988. View at Scopus
  24. H. C. Boyd, A. M. Gown, G. Wolfbauer, and A. Chait, “Direct evidence for a protein recognized by a monoclonal antibody against oxidatively modified LDL in atherosclerotic lesions from a Watanabe heritable hyperlipidemic rabbit,” American Journal of Pathology, vol. 135, no. 5, pp. 815–825, 1989. View at Scopus
  25. T. Kita, Y. Nagano, M. Yokode et al., “Probucol prevents the progression of atherosclerosis in Watanabe heritable hyperlipidemic rabbit, an animal model for familial hypercholesterolemia,” Proceedings of the National Academy of Sciences of the United States of America, vol. 84, no. 16, pp. 5928–5931, 1987. View at Scopus
  26. T. E. Carew, D. C. Schwenke, and D. Steinberg, “Antiatherogenic effect of probucol unrelated to its hypocholesterolemic effect: evidence that antioxidants in vivo can selectively inhibit low density lipoprotein degradation in macrophage-rich fatty streaks and slow the progression of atherosclerosis in the Watanabe heritable hyperlipidemic rabbit,” Proceedings of the National Academy of Sciences of the United States of America, vol. 84, no. 21, pp. 7725–7729, 1987.
  27. M. I. Cybulsky and M. A. Gimbrone Jr., “Endothelial expression of a mononuclear leukocyte adhesion molecule during atherogenesis,” Science, vol. 251, no. 4995, pp. 788–791, 1991. View at Scopus
  28. L. M. Buja, T. Kuta, and J. L. Goldstein, “Cellular pathology of progressive atherosclerosis in the WHHL rabbit. An animal model of familial hypercholesterolemia,” Arteriosclerosis, vol. 3, no. 1, pp. 87–101, 1983. View at Scopus
  29. M. E. Rosenfeld, T. Tsukada, A. M. Gown, and R. Ross, “Fatty streak initiation in Watanabe Heritable Hyperlipemic and comparably hypercholesterolemic fat-fed rabbits,” Arteriosclerosis, vol. 7, no. 1, pp. 9–23, 1987. View at Scopus
  30. M. E. Rosenfeld, T. Tsukada, A. Chait, E. L. Bierman, A. M. Gown, and R. Ross, “Fatty streak expansion and maturation in Watanabe heritable hyperlipidemic and comparably hypercholesterolemic fat-fed rabbits,” Arteriosclerosis, vol. 7, no. 1, pp. 24–34, 1987.
  31. T. Takano, K. Amanuma, J. Kimura, T. Kanaseki, and S. Ohkuma, “Involvement of macrophages in accumulation and elimination of cholesterol ester in atherosclerotic aorta,” Acta Histochemica et Cytochemica, vol. 19, no. 1, pp. 135–143, 1986.
  32. T. Tsukada, M. Rosenfeld, R. Ross, and A. M. Gown, “Immunocytochemical analysis of cellular components in atherosclerotic lesions. Use of monoclonal antibodies with the Watanabe and fat-fed rabbit,” Arteriosclerosis, vol. 6, no. 6, pp. 601–613, 1986. View at Scopus
  33. K. F. Kozarsky, D. K. Bonen, F. Giannoni, T. Funahashi, J. M. Wilson, and N. O. Davidson, “Hepatic expression of the catalytic subunit of the apolipoprotein B mRNA editing enzyme (apobec-1) ameliorates hypercholesterolemia in LDL receptor-deficient rabbits,” Human Gene Therapy, vol. 7, no. 8, pp. 943–957, 1996. View at Scopus
  34. M. Nakamuta, S. Taniguchi, B. Y. Ishida, K. Kobayashi, and L. Chan, “Phenotype interaction of apobec-1 and CETP, LDLR, and ApoE gene expression in mice: role of ApoB mRNA editing in lipoprotein phenotype expression,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 18, no. 5, pp. 747–755, 1998. View at Scopus
  35. B. Perret, L. Mabile, L. Martinez, F. Tercé, R. Barbaras, and X. Collet, “Hepatic lipase: structure/function relationship, synthesis, and regulation,” Journal of Lipid Research, vol. 43, no. 8, pp. 1163–1169, 2002. View at Scopus
  36. L. B. Agellon, A. Walsh, T. Hayek et al., “Reduced high density lipoprotein cholesterol in human cholesteryl ester transfer protein transgenic mice,” The Journal of Biological Chemistry, vol. 266, no. 17, pp. 10796–10801, 1991. View at Scopus
  37. Y. Watanabe, T. Ito, and M. Saeki, “Hypolipidemic effects of CS-500 (ML-236B) in WHHL-rabbit, a heritable animal model for hyperlipidemia,” Atherosclerosis, vol. 38, no. 1-2, pp. 27–31, 1981. View at Scopus
  38. M. Shiomi and T. Ito, “Pravastatin sodium, a competitive inhibitor of hepatic 3-hydroxy-3- methylglutaryl coenzyme a reductase, decreases the cholesterol content of newly secreted very-low-density lipoprotein in Watanabe heritable hyperlipidemic rabbits,” Metabolism, vol. 43, no. 5, pp. 559–564, 1994. View at Publisher · View at Google Scholar · View at Scopus
  39. M. Kuroda, A. Matsumoto, H. Itakura et al., “Effects of pravastatin sodium alone and in combination with cholestyramine on hepatic, intestinal and adrenal low density lipoprotein receptors in homozygous Watanabe heritable hyperlipidemic rabbits,” Japanese Journal of Pharmacology, vol. 59, no. 1, pp. 65–70, 1992. View at Scopus
  40. M. Shiomi, T. Ito, Y. Watanabe et al., “Suppression of established atherosclerosis and xanthomas in mature WHHL rabbits by keeping their serum cholesterol levels extremely low. Effect of pravastatin sodium in combination with cholestyramine,” Atherosclerosis, vol. 83, no. 1, pp. 69–80, 1990. View at Publisher · View at Google Scholar · View at Scopus
  41. Y. Watanabe, T. Ito, M. Shiomi et al., “Preventive effect of pravastatin sodium, a potent inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase, on coronary atherosclerosis and xanthoma in WHHL rabbits,” Biochimica et Biophysica Acta, vol. 960, no. 3, pp. 294–302, 1988. View at Scopus
  42. M. Shiomi, T. Ito, T. Tsukada et al., “Reduction of serum cholesterol levels alters lesional composition of atherosclerotic plaques: effect of pravastatin sodium on atherosclerosis in mature WHHL rabbits,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 15, no. 11, pp. 1938–1944, 1995. View at Scopus
  43. M. Shiomi and T. Ito, “Effect of cerivastatin sodium, a new inhibitor of HMG-CoA reductase, on plasma lipid levels, progression of atherosclerosis, and the lesional composition in the plaques of WHHL rabbits,” British Journal of Pharmacology, vol. 126, no. 4, pp. 961–968, 1999. View at Scopus
  44. M. Shiomi, T. Ito, Y. Hirouchi, and M. Enomoto, “Fibromuscular cap composition is important for the stability of established atherosclerotic plaques in mature WHHL rabbits treated with statins,” Atherosclerosis, vol. 157, no. 1, pp. 75–84, 2001. View at Publisher · View at Google Scholar · View at Scopus
  45. M. Shiomi, S. Yamada, and T. Ito, “Atheroma stabilizing effects of simvastatin due to depression of macrophages or lipid accumulation in the atheromatous plaques of coronary plaque-prone WHHL rabbits,” Atherosclerosis, vol. 178, no. 2, pp. 287–294, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  46. H. Otake, J. Shite, T. Shinke et al., “Relation between plasma adiponectin, high-sensitivity C-reactive protein, and coronary plaque components in patients with acute coronary syndrome,” American Journal of Cardiology, vol. 101, no. 1, pp. 1–7, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  47. M. B. Pepys, M. Baltz, and K. Gomer, “Serum amyloid P-component is an acute-phase reactant in the mouse,” Nature, vol. 278, no. 5701, pp. 259–261, 1979. View at Scopus
  48. J. Fan and T. Watanabe, “Transgenic rabbits as therapeutic protein bioreactors and human disease models,” Pharmacology and Therapeutics, vol. 99, no. 3, pp. 261–282, 2003. View at Publisher · View at Google Scholar · View at Scopus
  49. G. Liu, J. B. Iden, K. Kovithavongs, R. Gulamhusein, H. J. Duff, and K. M. Kavanagh, “In vivo temporal and spatial distribution of depolarization and repolarization and the illusive murine T wave,” Journal of Physiology, vol. 555, no. 1, pp. 267–279, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  50. B. London, “Cardiac arrhythmias: from (transgenic) mice to men,” Journal of Cardiovascular Electrophysiology, vol. 12, no. 9, pp. 1089–1091, 2001. View at Scopus
  51. G. C. Ness, Z. Zhao, and R. K. Keller, “Effect of squalene synthase inhibition on the expression of hepatic cholesterol biosynthetic enzymes, LDL receptor, and cholesterol 7α hydroxylase,” Archives of Biochemistry and Biophysics, vol. 311, no. 2, pp. 277–285, 1994. View at Publisher · View at Google Scholar · View at Scopus
  52. W. J. Schneider, M. S. Brown, and J. L. Goldstein, “Kinetic defects in the processing of the low density lipoprotein receptor in fibroblasts from WHHL rabbits and a family with familial hypercholesterolemia,” Molecular Biology & Medicine, vol. 1, no. 3, pp. 353–367, 1983. View at Scopus
  53. M. T. R. Subbiah, R. L. Yunker, Z. Rymaszewski, B. A. Kottke, and L. K. Bale, “Cholestyramine treatment in early life of low-density lipoprotein receptor deficient Watanabe rabbits: decreased aortic cholesteryl ester accumulation and atherosclerosis in adult life,” Biochimica et Biophysica Acta, vol. 920, no. 3, pp. 251–258, 1987. View at Scopus
  54. M. Shiomi and T. Ito, “MTP inhibitor decreases plasma cholesterol levels in LDL receptor-deficient WHHL rabbits by lowering the VLDL secretion,” European Journal of Pharmacology, vol. 431, no. 1, pp. 127–131, 2001. View at Publisher · View at Google Scholar · View at Scopus
  55. A. J. van Boven, J. W. Jukema, A. H. Zwinderman, H. J .G. M. Crijns, K. I. Lie, and A. V. G. Bruschke, “Reduction of transient myocardial ischemia with pravastatin in addition to the conventional treatment in patients with angina pectoris,” Circulation, vol. 94, no. 7, pp. 1503–1505, 1996.
  56. M. Shiomi, S. Yamada, Y. Amano, T. Nishimoto, and T. Ito, “Lapaquistat acetate, a squalene synthase inhibitor, changes macrophage/lipid-rich coronary plaques of hypercholesterolaemic rabbits into fibrous lesions,” British Journal of Pharmacology, vol. 154, no. 5, pp. 949–957, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  57. A. Mortensen, B. F. Hansen, J. F. Hansen et al., “Comparison of the effects of fish oil and olive oil on blood lipids and aortic atherosclerosis in Watanabe heritable hyperlipidaemic rabbits,” British Journal of Nutrition, vol. 80, no. 6, pp. 565–573, 1998. View at Scopus
  58. A. H. Lichtenstein and A. V. Chobanian, “Effect of fish oil on atherogenesis in Watanabe heritable hyperlipidemic rats,” Arteriosclerosis, vol. 10, no. 4, pp. 597–606, 1990. View at Scopus
  59. S. L. Pfister, M. Rosolowsky, J. M. Schmitz, F. J. Clubb, and W. B. Campbell, “Eicosapentaenoic acid alters vascular reactivity and platelet adhesion in Watanabe heritable hyperlipidemic rabbits,” European Journal of Pharmacology, vol. 161, no. 1, pp. 85–89, 1989. View at Scopus
  60. S. Rich, J. F. Miller, S. Charous et al., “Development of atherosclerosis in genetically hyperlipidemic rabbits during chronic fish-oil ingestion,” Arteriosclerosis, vol. 9, no. 2, pp. 189–194, 1989. View at Scopus
  61. F. J. Clubb, J. M. Schmitz, M. M. Butler, L. M. Buja, J. T. Willerson, and W. B. Campbell, “Effect of dietary omega-3 fatty acid on serum lipids, platelet function, and atherosclerosis in Watanabe Heritable Hyperlipidemic rabbits,” Arteriosclerosis, vol. 9, no. 4, pp. 529–537, 1989. View at Scopus
  62. T. Kita, Y. Nagano, M. Yokode et al., “Probucol prevents the progression of atherosclerosis in Watanabe heritable hyperlipidemic rabbit, an animal model for familial hypercholesterolemia,” Proceedings of the National Academy of Sciences of the United States of America, vol. 84, no. 16, pp. 5928–5931, 1987. View at Scopus
  63. T. E. Carew, D. C. Schwenke, and D. Steinberg, “Antiatherogenic effect of probucol unrelated to its hypocholesterolemic effect: evidence that antioxidants in vivo can selectively inhibit low density lipoprotein degradation in macrophage-rich fatty streaks and slow the progression of atherosclerosis in the Watanabe heritable hyperlipidemic rabbit,” Proceedings of the National Academy of Sciences of the United States of America, vol. 84, no. 21, pp. 7725–7729, 1987.
  64. F. de Nigris, T. Youssef, S. Ciafré et al., “Evidence for oxidative activation of c-Myc-dependent nuclear signaling in human coronary smooth muscle cells and in early lesions of Watanabe heritable hyperlipidemic rabbits: protective effects of vitamin E,” Circulation, vol. 102, no. 17, pp. 2111–2117, 2000. View at Scopus
  65. N. Yoshida, H. Murase, T. Kunieda et al., “Inhibitory effect of a novel water-soluble vitamin E derivative on atherosclerosis in rabbits,” Atherosclerosis, vol. 162, no. 1, pp. 111–117, 2002. View at Publisher · View at Google Scholar · View at Scopus
  66. N. Yamada, S. Ishibashi, H. Shimano et al., “Role of monocyte colony-stimulating factor in foam cell generation,” Proceedings of the Society for Experimental Biology and Medicine, vol. 200, no. 2, pp. 240–244, 1992. View at Scopus
  67. J. Shindo, T. Ishibashi, K. Yokoyama et al., “Granulocyte-macrophage colony-stimulating factor prevents the progression of atherosclerosis via changes in the cellular and extracellular composition of atherosclerotic lesions in Watanabe heritable hyperlipidemic rabbits,” Circulation, vol. 99, no. 16, pp. 2150–2156, 1999. View at Scopus
  68. A. V. Chobanian, C. C. Haudenschild, C. Nickerson, and S. Hope, “Trandolapril inhibits atherosclerosis in the Watanabe heritable hyperlipidemic rabbit,” Hypertension, vol. 20, no. 4, pp. 473–477, 1992. View at Scopus
  69. S. Hope, P. Brecher, and A. V. Chobanian, “Comparison of the effects of AT receptor blockade and angiotensin converting enzyme inhibition on atherosclerosis,” American Journal of Hypertension, vol. 12, no. 1 I, pp. 28–34, 1999. View at Publisher · View at Google Scholar · View at Scopus
  70. H. Koike, “New pharmacologic aspects of CS-866, the newest angiotensin II receptor antagonist,” American Journal of Cardiology, vol. 87, no. 8, supplement 1, pp. 33c–36c, 2001. View at Scopus
  71. T. Imanishi, A. Kuroi, H. Ikejima et al., “Effects of angiotensin converting enzyme inhibitor and angiotensin II receptor antagonist combination on nitric oxide bioavailability and atherosclerotic change in Watanabe heritable hyperlipidemic rabbits,” Hypertension Research, vol. 31, no. 3, pp. 575–584, 2008. View at Publisher · View at Google Scholar · View at Scopus
  72. T. Imanishi, H. Tsujioka, H. Ikejima et al., “Renin inhibitor aliskiren improves impaired nitric oxide bioavailability and protects against atherosclerotic changes,” Hypertension, vol. 52, no. 3, pp. 563–572, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  73. J. L. M. van Niekerk, Th. Hendriks, H. H. M. de Boer, and A. Van 't Laar, “Does nifedipine suppress atherogenesis in WHHL rabbits?” Atherosclerosis, vol. 53, no. 1, pp. 91–98, 1984. View at Scopus
  74. A. V. Chobanian, “The effects of ACE inhibitors and other antihypertensive drugs on cardiovascular risk factors and atherogenesis,” Clinical Cardiology, vol. 13, no. 6, pp. VII43–VII48, 1990. View at Scopus
  75. H. Hosomi, S. Katsuda, and Y. Watanabe, “Effect of atherosclerosis on the responsiveness of the rapidly acting arterial pressure control system in WHHL rabbits,” Cardiovascular Research, vol. 20, no. 3, pp. 195–200, 1986. View at Scopus
  76. M. Sata and D. Fukuda, “Crucial role of renin-angiotensin system in the pathogenesis of atherosclerosis,” Journal of Medical Investigation, vol. 57, no. 1-2, pp. 12–25, 2010. View at Scopus
  77. M. Ogawa, S. Ishino, T. Mukai et al., “F-FDG accumulation in atherosclerotic plaques: immunohistochemical and PET imaging study,” Journal of Nuclear Medicine, vol. 45, no. 7, pp. 1245–1250, 2004. View at Scopus
  78. J. Meding, M. Urich, K. Licha et al., “Magnetic resonance imaging of atherosclerosis by targeting extracellular matrix deposition with Gadofluorine M,” Contrast Media & Molecular Imaging, vol. 2, no. 3, pp. 120–129, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  79. H. Steen, J. A. C. Lima, S. Chatterjee et al., “High-resolution three-dimensional aortic magnetic resonance angiography and quantitative vessel wall characterization of different atherosclerotic stages in a rabbit model,” Investigative Radiology, vol. 42, no. 9, pp. 614–621, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  80. A. Iwata, S. I. Miura, S. Imaizumi, B. Zhang, and K. Saku, “Measurement of atherosclerotic plaque volume in hyperlipidemic rabbit aorta by intravascular ultrasound,” Journal of Cardiology, vol. 50, no. 4, pp. 229–234, 2007. View at Scopus
  81. M. Ogawa, Y. Magata, T. Kato et al., “Application of F-FDG PET for monitoring the therapeutic effect of antiinflammatory drugs on stabilization of vulnerable atherosclerotic plaques,” Journal of Nuclear Medicine, vol. 47, no. 11, pp. 1845–1850, 2006. View at Scopus